知镜 Cognispect · 医学文献与研究工作台

Baseline Hematologic Reserve and Laboratory-Defined Leukopenia/Neutropenia During Vancomycin Therapy: A Real-World Risk-Stratification Cohort Study.

Wu D, Wang X, Chen C, Wang X, Li H, Zhao L, Li G, Wang X.
The Annals of pharmacotherapy · 2026-08-27 · PMID 42661431

文献摘要

Background Laboratory-defined leukopenia/neutropenia may occur during vancomycin therapy, but mild threshold-crossing abnormalities do not necessarily establish definite drug-induced toxicity. Objective To develop and evaluate a risk-stratification strategy based on baseline hematologic reserve and vancomycin treatment duration. Methods This single-center retrospective cohort included adult inpatients receiving intravenous vancomycin for ≥3 days. Patients with baseline leukopenia/neutropenia, hematologic disease, malignancy or antitumor therapy, non-intravenous use, or unavailable blood counts were excluded. The primary endpoint was laboratory-defined leukopenia/neutropenia, defined as new white blood cell count (WBC) 9 /L or absolute neutrophil count (ANC) 9 /L during therapy or within 3 days after discontinuation. A 4-component baseline hematologic reserve score was constructed from WBC, ANC, monocyte count, and hemoglobin. Results Among 506 patients, 75 developed leukopenia/neutropenia, corresponding to an event rate of 14.8%. The score assigned 1 point each for WBC ≤7.77 × 10 9 /L, ANC ≤6.62 × 10 9 /L, monocyte count ≤0.40 × 10 9 /L, and hemoglobin ≤102 g/L. Event rates increased from 7.5% to 40.9% across scores of 0 to 4 ( P for trend P 14 days was also independently associated with the outcome (adjusted OR 5.08, 95% CI, 2.77-9.29, P 14 days, with an event rate of 75.0%. The baseline score model showed moderate performance (area under the curve [AUC] 0.697), whereas the extended model incorporating the score-defined risk group, treatment duration, and clinical covariates improved discrimination (AUC 0.786). Conclusion and relevance A 4-component baseline hematologic reserve score combined with treatment duration may help identify patients who warrant closer complete blood count monitoring during vancomycin therapy. These findings should be interpreted as laboratory-event risk stratification rather than proof of definite vancomycin-induced toxicity or as a mandatory discontinuation threshold.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。